Reducing Common Cause Variation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reducing Common Cause Variation
Where is the variability coming from and what have we done to minimize it?


Pharmaceutical Technology
Volume 36, Issue 2, pp. 32


PHOTODISC/GETTY IMAGES
Textbooks and journal articles treat common cause variation as if it is an inevitable fact of nature and beyond our control: "In any production process, regardless of how well-designed or carefully maintained it is, a certain amount of inherent or natural variability will always exist. This natural variability or 'background noise' is the cumulative effect of many small, essentially unavoidable causes" [Emphasis added] (1). This attitude cuts off thoughts of trying to reduce variation. But, with some reflection, there are several ideas and techniques that can begin to help reduce common cause variation.

Work to hit the target


Lynn D. Torbeck
Aiming for and hitting the target, whether it is x, y or z, seems a simple idea, but it could be argued that it is everybody's responsibility to know what the target is and to do everything possible to hit that target every time. One person achieving the target infrequently doesn't help. But 400 people hitting targets a dozen times a day can have a dramatic effect on reducing variability. The target could be something as simple as setting the temperature on a dryer or as complex as a management objective. Keep in mind that a specification range is not a playground for manufacturing.

This mindset also can influence how specifications criteria are written. It is common to write the criteria as "(Low, High)." I suggest that criteria are better written as, "Target (Low, High)." The first thing the operator sees is the target value; people generally try to achieve the first thing they see. Second, the low and high criteria limits are given, which eliminates the need to mentally calculate those limits (e.g., if Target ±Δ, was used instead). The limits need not be symmetrical with the target value.

Flexible consistency

The terms sound contradictory but do contain logic. Many activities are at the liberty of the operator or analyst and, as such, are subject to considerable leeway in how they are performed. In these situations, particularly in the analytical laboratory, one strives to get everybody on the team to do exactly the same thing, the same way, every time. If then, at some point in the future someone proposes a new or better way to perform the task, the whole team changes to follow the new process. This group consistency can have a substantial impact on variation within a department. Notably, creativity of the individual is not stifled, but rather channeled to find better ways to perform a task.

Operational definitions

"An operational definition describes what something is and how it is measured" (2). For example, "sample the batch" could mean: "Using the 72 in. thief, open the port on the right side labeled P8, and take a sample from the top two inches, a sample from the middle, and a sample two inches from the bottom. Composite the three samples into a clean glass jar with a lid, and label with the date, time, name, product, lot and vat number." Operational definitions reduce variation by promoting consistency. Standard operating procedures are a form of operational definitions.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here